MedTrace Logo

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

NCT05159700 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-12-15

No results posted yet for this study

Summary

This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.

Conditions

  • Advanced Solid Tumor
  • Advanced Solid Malignancies

Interventions

DRUG

PRJ1-3024

PRJ1-3024 is provided as capsules and is administered orally once a day.

Sponsors & Collaborators

  • Zhuhai Yufan Biotechnologies Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yang Xu, PhD · Head of US Clinical Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2024-07-17
Completion
2026-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05159700 on ClinicalTrials.gov